Small Pharma alternatives
10 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓
Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About Small Pharma and its alternatives
Users exploring Small Pharma alternatives often seek other biotech firms advancing novel central nervous system treatments or psychedelic-inspired therapeutics. Small Pharma focuses on DMT-based candidates for mental health conditions, prompting comparisons around clinical-stage pipelines, regulatory progress, and funding models. Searchers compare trial designs, intellectual property strength, and partnership strategies when evaluating options that address similar depression or anxiety indications. Decision makers review companies with differing molecule focuses, delivery methods, or geographic footprints to find the best fit for investment, collaboration, or competitive intelligence needs.
Explore the alternatives
1.Gilgamesh Pharmaceuticals
Healthcare & MedicalGilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
2.ATAI Life Sciences
Healthcare & MedicalCreating breakthroughs in mental health
3.Beckley Psytech
Healthcare & MedicalCreating breakthroughs in mental health
4.COMPASS Pathways
Healthcare & MedicalBiotech advancing psilocybin therapy for treatment-resistant mental health conditions
5.Cybin
Healthcare & MedicalPioneering next-generation serotonergic agonist therapies for durable mental health improvements
- D
6.Delix Therapeutics
Healthcare & MedicalRepairing the Brain to Heal the Mind
7.Johnson & Johnson
Healthcare & MedicalChanging health for humanity
8.Lundbeck
Healthcare & MedicalAdvancing brain health. Transforming lives.
9.MindMed
Healthcare & Medical
10.Seelos Therapeutics
Healthcare & MedicalDeveloping therapies for CNS disorders and rare diseases
See more comparisons in Healthcare & Medical alternatives.
Questions about Small Pharma alternatives
What companies offer similar DMT or psychedelic therapy pipelines to Small Pharma?
Competitors include firms developing 5-MeO-DMT, psilocybin, or LSD derivatives with comparable Phase 2 mental health programs and regulatory strategies.
How does Small Pharma's clinical trial progress compare to other CNS drug developers?
Small Pharma has completed early DMT studies; alternatives vary in Phase advancement, patient enrollment speed, and endpoint selection for depression trials.
Which alternatives to Small Pharma have stronger partnerships or larger funding rounds?
Several peers have secured major pharma collaborations or raised significantly higher capital, affecting development timelines and commercialization reach.
Are there oral or non-IV alternatives to Small Pharma's administration method?
Some competing programs explore different routes such as oral, sublingual, or intramuscular delivery for improved patient convenience and scalability.
What regulatory pathways are competitors using versus Small Pharma?
Alternatives pursue FDA breakthrough designation, EMA orphan status, or UK MHRA scientific advice with varying success rates and timelines.
How do market caps and investor profiles differ among Small Pharma alternatives?
Publicly traded peers often show higher valuations and broader institutional ownership compared with private-stage companies in the same space.